The patent work is progressing ahead and our IP will be protected. OWCP has 31 registered patents in 9 patent families. Epic R&D team, $5 MILLION funding from an Institutional Investor... This is huge!
Awesome find Potvinsux !!!
Potvinsux Friday, 05/04/18 11:59:57 AM Post # 138606
This is amazing! A lot of time was spent to record the dosages, effects, and the patients' reactions to various form of deliveries.
Relieving from Fibromyalgia syndrome symptoms!
$OWCP got the IP on treatment of Fibromyalgia protected!
************************* 88. A composition comprising a therapeutically effective amount of Tetrahydrocannabinol (THC) or a derivative thereof, or Cannabidiol (CBD) or a derivative thereof, or a combination thereof for use in relieving a subject suffering from fibromyalgia syndrome symptoms.
89. The composition of claim 88, wherein at least one of the following holds true: a) said Tetrahydrocannabinol (THC) or a derivative thereof, or said Cannabidiol (CBD) or a derivative thereof is from cannabis extract; b) said THC a derivative thereof is selected from the group consisting of THC, Tetrahydrocannabivarin (THCV), Tetrahydrocannabinolic acid (THCA) and any combination thereof; c) said THC or a derivative thereof is selected from the group consisting of natural THC or a derivative thereof produced in the body of humans and animals, THC or a derivative thereof extracted from plants, synthetic THC or a derivative thereof, and any combination thereof; d) said THC or a derivative thereof is extracted from cannabis; said cannabis is selected from the group comprising of: Cannabis sativa, Cannabis indica, Cannabis ruderalis, and any combination thereof; e) said cannabidiol (CBD) or a derivative thereof is selected from the group consisting of CBD, cannabidivarin (CBDV), cannabidiolic acid (CBDA) and any combination thereof; f) said CBD or a derivative thereof is selected from the group consisting of natural CBD or a derivative thereof produced in the body of humans and animals, CBD or a derivative thereof extracted from plants, synthetic CBD or a derivative thereof, and any combination thereof; g) said CBD or a derivative thereof is extracted from cannabis; said cannabis is selected from a group consisting of: Cannabis sativa, Cannabis indica, Cannabis ruderalis, and any combination thereof; h) the concentration of said THC is in the range of about 2% to about 85%; and i) the concentration of said CBD is in the range of about 2% to about 85%.
90. The composition of claim 88, further comprising a ratio of said THC, or a derivative thereof, to said CBD, or a derivative thereof of 4:1 or 5:1, respectively.
91. The composition of claim 88, wherein said composition is formulated for administration of at least one of: a) between about 10 mg THC and about 160 mg THC per day, preferably between about 10 mg and about 100 mg THC per day; b) between about 5 mg THC and about 20 mg THC per dosage unit, preferably about 10 mg THC per dosage unit; c) between about 2 mg CBD and about 40 mg CBD per day, preferably between about 2 mg and about 20 mg CBD per day; d) between about 1 mg CBD and about 5 mg CBD per dosage unit, preferably about 2 mg CBD per dosage unit; and e) about 1 to about 10 times per day.
92. The composition of claim 88, wherein at least one of the following holds true: a) said composition is administered in a manner selected from the group consisting of: intranasal, transdermal, topical, intravenous, oral, and any combination thereof; b) said composition is formulated in the form of drops; c) said composition is formulated in a dosage form selected from the group consisting of oil, liquid, solid, gas, oral, pill, tablet, capsule, buccal, sub-lingual, orally-disintegrating, thin film, liquid solution, suspension, powder or liquid or solid crystals, pastes, inhalational, aerosol, inhaler, nebulizer, smoking, vaporizer, parenteral, intradermal, intramuscular, intraosseous, intraperitoneal, intravenous, subcutaneous, topical, cream, gel, liniment or balm, lotion, ointment, drops, skin patch, vaginal, suppository, pessary, rectal and any combination thereof; and d) said composition is administered in combination with at least one therapeutic agent selected from the group comprising of dypirone, pregabalin, duloxetine, milnacipran, tricyclic antidepressants, amitriptyline, gabapentin, paracetamol, tramadol, codeine, growth hormone, sodium oxybate, cyclobenzaprine, tizanidine, pramipexole, ropinirole, quercetin and any combination thereof.
93. The composition according to claim 92, wherein said composition provides a synergistic effect with respect to treatment of fibromyalgia when administered in combination with said therapeutic agent, as compared to the effect provided when said composition and said therapeutic agent administered separately.
94. The composition of claim 88, wherein at least one of the following holds true: a) said composition additionally comprises at least one carrier or excipient selected from the group consisting of diluents, antiadherents, binders, coatings, disintegrants, surfactants, dissolving agents, solubilising agents, bioadhesive agents, polysaccharides, polymers, copolymers, fast dissolving tablet (FDT) type excipient, bioavailability enhancing agent, Thin Film type excipient, PharmFilm type excipient, mucoadhesive type excipient, acidifying agents, probiotic agents, protective agents, antioxidants, effervescent excipient, dispersing agents flavours, colours, lubricants, glidants, sorbents, preservatives, sweeteners, and any combination thereof; b) said composition further comprising flavoring agents, selected from the group consisting of sugar, sucrose, sorbitol, sucralose, saccharin sodium, sodium cyclamate, aspartame, neotame, acesulfame potassium, stevioside, sodium chloride, D-limonene, citric acid and any combination thereof; c) said composition further comprising preservatives, selected from the group consisting of methylparabens, ethylparabens, propylparabens, butylparabens, sorbic acid, acetic acid, propionic acid, sulfites, nitrites, sodium sorbate, potassium sorbate, calcium sorbate, benzoic acid, sodium benzonate, potassium benzonate, calcium benzonate, sodium metabisulfite, propylene glycol, benzaldehyde, butylated hydroxytoluene, butylated hydroxyanisole, formaldehyde donors, essential oils, monoglyceride, phenol, mercury components and any combination thereof; d) said composition is in a sustained release dosage form or in an immediate release dosage form; and e) said composition is in a sustained release dosage form selected from the group comprising of liposomes, drug polymer conjugates, microencapsulation, controlled-release tablet coating, and any combination thereof.
95. The composition of claim 88, wherein said composition is used for preventing the onset of a flareup of fibromyalgia symptoms in said subject.
96. The composition of claim 88, wherein said composition provides an improvement in fibromyalgia symptoms of said subject as measured by at least one pain severity scale, compared to an established baseline, control or placebo.
97. The composition of claim 96, wherein at least one of the following holds true: a) said improvement in fibromyalgia symptoms is measured by an improvement in the subject's score of at least one point on said at least one pain severity scale, as compared to an established baseline or to a placebo; b) said at least one pain severity scale is selected from the group comprising of Brief pain inventory (BPI), Sleep history questionnaire (PSQI), SF-36 Quality of life assessment, Fibromyalgia impact questionnaire (FIQ), Mini International Neuropsychiatric Interview, Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Rating Scale for Depression (HRSD), fibromyalgia syndrome Tenderness Assessment, Hamilton Depression Rating Scale (HORS) and any combination thereof; c) said fibromyalgia symptoms are selected from the group comprising of widespread pain, chronic pain, cognitive difficulties, chronic muscle pain, muscle spasms, muscle tightness, fatigue, insomnia, stiffness, fibro fog, abdominal pain, bloating, nausea, constipation, diarrhea, headache, jaw and facial tenderness, anxiety, depression, numbness or tingling in the limbs, irritable bladder, feeling of swelling, painful menstruation, restless leg, dizziness, female or subject with established FMS confirmed by the 1990 ACR and any combination thereof; and d) a sensitivity to at least one of the following: odors, noise, bright lights, medications, certain foods, and cold.
98. The composition of claim 97, wherein said composition provides at least one of: a) an improvement in fibromyalgia symptoms of said subject measured by a score on the average pain severity item of the BPI scale of above 5; b) a reduction in BPI score from baseline to endpoint; and c) a sustained response defined as a 30% reduction from baseline to endpoint in the BPI score with a 30% reduction from baseline at least 2 weeks prior to the last, and with at least a 20% reduction from baseline at every week in between.
99. The composition of claim 88, wherein said composition provides at least one of: a) an improvement in pain severity as measured by the self-reported Brief Pain Inventory (short form) average pain severity score fibromyalgia impact questionnaire items; and b) improvement in measures selected from the group consisting of: quality of life, quality of sleep, disability, depression, anxiety and the patient global impression of change and the fibromyalgia severity score.
100. The composition of claim 99, Wherein said pain severity score fibromyalgia impact questionnaire items comprising items which measure physical function, pain assessment, fatigue and distress.
101. A method for treating a subject suffering from fibromyalgia syndrome comprising steps of administering to said subject a composition comprising a therapeutically effective amount of Tetrahydrocannabinol (THC) or a derivative thereof, or Cannabidiol (CBD) or a derivative thereof, or a combination thereof in a therapeutically effective dosage.
102. The method of claim 101, additionally comprising at least one step selected from the group consisting of: a) formulating said composition to comprise a ratio of said THC, or a derivative thereof, to said CBD, or a derivative thereof, of 4:1 or 5:1, respectively; b) administering said THC or a derivative thereof in a dosage unit of between about 5 mg THC and about 20 mg THC, preferably about 10 mg THC per dosage unit; c) administering said CBD or a derivative thereof in a dosage of between about 2 mg CBD and about 40 mg CBD per day, preferably between about 2 mg and about 20 mg CBD per day; d) administering said CBD or a derivative thereof in a dosage unit of between about 1 mg CBD and about 5 mg CBD, preferably about 2 mg CBD per dosage unit; e) formulating said composition in a dosage form of drops; f) preventing the onset of a fibromyalgia flareup in said subject; g) improving fibromyalgia symptoms of said subject as measured by at least one pain severity scale, compared to an established baseline, control or placebo; h) providing an improvement in fibromyalgia symptoms of said subject measured by a score on the average pain severity item of the BPI scale of above 5; i) providing a reduction in BPI score from baseline to endpoint; j) providing a sustained response defined as a 30% reduction from baseline to endpoint in the BPI score with a 30% reduction from baseline at least 2 weeks prior to the last, and with at least a 20% reduction from baseline at every week in between; and k) providing an improvement in pain severity as measured by the self-reported Brief Pain Inventory (short form) average pain severity score fibromyalgia impact questionnaire items.
103. The method of claim 102, wherein at least one of the following folds true: a) the method additionally comprising steps of performing blood tests for CBD and THC 1 hour and 2 hours after said dosage unit intake; b) the method additionally comprising steps of selecting said fibromyalgia symptoms to be a sensitivity to at least one of the following: odors, noise, bright lights, medications, certain foods, and cold; and c) said pain severity score fibromyalgia impact questionnaire items comprising items which measure physical function, pain assessment, fatigue and distress.
104. The method of claim 103, additionally comprising steps of providing improvement in measures selected from the group consisting of: quality of life, quality of sleep, disability, depression, anxiety and the patient global impression of change and the fibromyalgia severity score.
105. A composition comprising a therapeutically effective amount of cannabis formulation for use in relieving a subject suffering from fibromyalgia syndrome symptoms, wherein said cannabis formulation contains synthetic components of cannabis.
106. The composition of claim 105, wherein at least one of the following holds true: a) said synthetic components are synthetically produced tetrahydrocannabinol (THC) or a derivative thereof, or cannabidiol (CBD) or a derivative thereof, or a combination thereof; b) said composition comprising a ratio of said THC, or a derivative thereof, to said CBD, or a derivative thereof, of 4:1 or 5:1, respectively; c) said composition is formulated for administration of between about 10 mg THC and about 160 mg THC per day, preferably between about 10 mg and about 100 mg THC per day; and d) said composition is formulated for administration of about 2 mg CBD and about 40 mg CBD per day, preferably between about 2 mg CBD and about 20 mg CBD per day.
107. A method for preventing the risk for the onset of a fibromyalgia flareup, wherein said method comprises steps of: a) formulating a composition comprising tetrahydrocannabinol (THC) or a derivative thereof, or cannabidiol (CBD) or a derivative thereof, or a combination thereof; and b) administering said composition to a subject in risk for suffering from a fibromyalgia flareup according to a predetermined protocol.
108. The method of claim 107, wherein at least one of the following holds true: a) said step of formulating further comprises formulating said composition comprises a ratio of said THC, or a derivative thereof, to said CBD, or a derivative thereof, of 4:1 or 5:1, respectively; b) said method additionally comprising steps of administering said THC or a derivative thereof in a dosage of about 10 mg THC and about 160 mg THC per day, preferably between about 10 mg THC and about 100 mg THC per day per day; and c) said method additionally comprising steps of administering said CBD or a derivative thereof in a dosage of about 2 mg CBD and about 40 mg CBD per day, preferably between about 2 mg CBD and about 20 mg CBD per day.
$$$$$ OWCP $$$$$
YOU ARE A GHOST DRIVING A MEAT COATED SKELETON MADE FROM STARDUST RIDING A ROCK FLOATING THROUGH SPACE. FEAR NOTHING!
